Imfinzi (durvalumab) Patient Assistance Program
Don’t let the high cost of brand anti-PD-L1 immunotherapy disrupt your lung, biliary, hepatocellular, or endometrial cancer treatment. We help eligible patients access Imfinzi (durvalumab intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Imfinzi (durvalumab) is FDA-approved across multiple indications: stage III unresectable NSCLC after chemoradiation (PACIFIC), extensive-stage small cell lung cancer (with platinum/etoposide — CASPIAN), limited-stage small cell lung cancer (after chemoradiation — ADRIATIC), biliary tract cancer (with gemcitabine + cisplatin — TOPAZ-1), hepatocellular carcinoma (with Imjudo/tremelimumab — HIMALAYA), advanced endometrial cancer (with chemo and pembrolizumab in MMR-deficient — RUBY), muscle-invasive bladder cancer (perioperative with chemo — NIAGARA). Anti-PD-L1 monoclonal antibody — checkpoint inhibitor.
- Without assistance, Imfinzi costs commonly run approximately $14,000–$18,000 per dose (every 3 or 4 weeks depending on regimen and indication).
- Through AffordMyPrescriptions, qualifying patients can access Imfinzi for a flat $69.95 per month.
- Other PD-1/PD-L1 inhibitors: pembrolizumab (Keytruda — broadest oncology indications, including a 6-weekly dosing option; also Keytruda Qlex SC formulation now available), nivolumab (Opdivo and Opdivo Qvantig SC — broad oncology indications), atezolizumab (Tecentriq — also Tecentriq Hybreza SC), cemiplimab (Libtayo — cutaneous SCC, NSCLC), dostarlimab (Jemperli — dMMR endometrial and dMMR solid tumors), tislelizumab (Tevimbra — esophageal SCC), retifanlimab (Zynyz — Merkel cell). Combinations: Opdualag (nivolumab + relatlimab for melanoma), Imfinzi + Imjudo (durvalumab + tremelimumab for HCC and NSCLC).
What is Imfinzi Prescription Assistance Program?
The Imfinzi Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Imfinzi (used across multiple cancer indications as an anti-PD-L1 checkpoint inhibitor) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, indication-specific documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Imfinzi PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including diagnosis, staging, biomarker testing where relevant, prior therapy history, and indication-specific criteria), follow up with the manufacturer’s program until approval, manage your infusion cycles, and handle annual re-certification — so you never face a gap in your Imfinzi checkpoint inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Imfinzi enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cancer treatment.
Pharmacy Price Comparison
- Without assistance, Imfinzi costs thousands of dollars per infusion at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this immunotherapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Imfinzi advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Tecentriq (alt PD-L1) | ~$13,000/dose | Alt PD-L1 inhibitor |
| Hospital oncology | ~$17,500/dose | Save substantially |
| Community oncology | ~$16,000/dose | Save substantially |
| Specialty pharmacy | ~$15,000/dose | Save substantially |
| 340B-eligible institution | ~$14,000/dose | Save substantially |
| Keytruda (alt PD-1) | ~$13,500/dose | Alt PD-1 inhibitor |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Imfinzi — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Imfinzi Prescription Program?
The Imfinzi Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Multiple PD-1/PD-L1 checkpoint inhibitors are available — choice often guided by FDA-approved indications, regimen, and insurance.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Imfinzi assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Imfinzi is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Imfinzi:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $14,000–$18,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Imfinzi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Imfinzi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Imfinzi:
Imfinzi is an anti-PD-L1 monoclonal antibody that blocks PD-L1 from engaging PD-1 on T cells — releasing T-cell suppression and enabling anti-tumor immune response. Multiple FDA approvals across lung (NSCLC and SCLC), biliary, hepatocellular, endometrial, and bladder cancers. Often combined with chemotherapy, radiation, or other immunotherapy (Imjudo) depending on regimen.
How It Works:
Tumor cells often express PD-L1 — engaging PD-1 on T cells to suppress anti-tumor immunity. This ‘checkpoint’ allows tumor evasion of immune surveillance. Durvalumab is a fully human IgG1 anti-PD-L1 antibody that blocks PD-L1 binding to both PD-1 and CD80 — releases T-cell suppression, restores anti-tumor immunity. Combinations with chemotherapy (CASPIAN, TOPAZ-1, NIAGARA), chemoradiation consolidation (PACIFIC, ADRIATIC), and dual checkpoint blockade with anti-CTLA-4 tremelimumab (HIMALAYA, POSEIDON) extend benefit across cancer types and stages.
Form and Use:
Imfinzi IV infusion. Dosing varies by indication: 10 mg/kg every 2 weeks (some regimens), 1500 mg every 4 weeks (consolidation, biliary), 1500 mg with chemo every 3 weeks then every 4 weeks maintenance, or 20 mg/kg with Imjudo (single-dose tremelimumab in HIMALAYA). Premedication generally not required. Continue until progression or unacceptable toxicity per protocol; duration varies by indication (e.g., 1 year for PACIFIC consolidation, indefinite for advanced metastatic disease).
Generic Availability:
No biosimilar/generic. Other PD-1 inhibitors: pembrolizumab (Keytruda — broadest oncology indications, also Keytruda Qlex SC), nivolumab (Opdivo and Opdivo Qvantig SC), cemiplimab (Libtayo), dostarlimab (Jemperli), tislelizumab (Tevimbra). Other PD-L1 inhibitors: atezolizumab (Tecentriq, Tecentriq Hybreza SC), avelumab (Bavencio). Anti-CTLA-4: ipilimumab (Yervoy), tremelimumab (Imjudo — only approved in combinations). Combinations: Opdualag (nivolumab + relatlimab), Imfinzi + Imjudo, Opdivo + Yervoy. Choice driven by FDA-approved indication, biomarker status (PD-L1 expression, MMR/MSI, TMB), regimen, and insurance coverage. NCCN guidelines for each cancer type guide selection.
Warnings:
Immune-related adverse events (irAEs) — checkpoint inhibitor class effect that can affect any organ system: pneumonitis (sometimes fatal — evaluate respiratory symptoms), colitis (manage promptly to prevent perforation), hepatitis, endocrinopathies (thyroid, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis, dermatitis (including SJS/TEN rare), neurologic (Guillain-Barré, myasthenia gravis, encephalitis), cardiac (myocarditis — sometimes fatal), pancreatitis, ocular, hematologic. Infusion-related reactions, embryo-fetal toxicity, allogeneic stem cell transplant complications (GVHD if subsequent). Many irAEs require corticosteroids and may require permanent discontinuation. Patient and clinician education on irAE recognition essential. Combination with Imjudo (anti-CTLA-4) increases irAE rates substantially.
FAQ (Frequently Asked Questions)
How much does Imfinzi cost without insurance?
$14,000–$18,000 per dose. Annualized cost can exceed $200,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this immunotherapy.
Is Imfinzi considered chemotherapy?
No — Imfinzi is immunotherapy (an anti-PD-L1 checkpoint inhibitor) — releases T-cell brakes to enable anti-tumor immune response. Different mechanism and toxicity profile from cytotoxic chemotherapy, but often combined with chemotherapy in many regimens.
What is the difference between Imfinzi and Keytruda or Tecentriq?
All are checkpoint inhibitors. Keytruda (pembrolizumab) and Opdivo (nivolumab) are anti-PD-1 (block PD-1 receptor on T cells). Imfinzi (durvalumab) and Tecentriq (atezolizumab) are anti-PD-L1 (block PD-L1 on tumor cells). Functionally similar but FDA-approved indications differ — choice driven by approved use and clinical context.
What are immune-related adverse events (irAEs) and how serious are they?
Checkpoint inhibitors can release immune brakes throughout the body — autoimmune-like inflammation can affect any organ system. Lungs (pneumonitis), GI (colitis, hepatitis), endocrine (thyroid, adrenal, pituitary, diabetes), kidney, skin, neurologic, and cardiac (myocarditis) toxicities can be severe and require prompt corticosteroid treatment. Some events are permanent and require lifelong hormone replacement. Patient and family education on early warning signs is essential.
What is the difference between Imfinzi alone and Imfinzi + Imjudo?
Imfinzi alone is anti-PD-L1. The combination adds Imjudo (tremelimumab anti-CTLA-4) — dual checkpoint blockade for stronger immune activation but substantially higher irAE rates. Used in HCC (HIMALAYA — single high-dose Imjudo + ongoing Imfinzi) and NSCLC (POSEIDON — Imjudo + Imfinzi + chemo).
Take Control of Your Medication Costs
Checkpoint inhibitor immunotherapy should not be derailed by cost. Our Imfinzi advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Imfinzi through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.